Home / Deep Research / Mucolipidosis Type III Alpha/Beta

Mucolipidosis Type III Alpha/Beta

Mucolipidosis Type III Alpha/Beta Deep Research Fallback

⚠️ Fallback MONDO:0018931

Mucolipidosis Type III Alpha/Beta Deep Research Fallback

Provider Attempts

  • 2026-05-08T04:39Z: just research-disorder openai Mucolipidosis_Type_III_Alpha_Beta was attempted before the YAML existed and failed immediately because the disorder file was not found.
  • 2026-05-08T04:53Z: just research-disorder openai Mucolipidosis_Type_III_Alpha_Beta started after YAML creation but produced no output during the bounded wait. The provider process did not accept stdin interrupt through the session, so the process tree was terminated with SIGTERM.

No provider-generated deep-research narrative was available within the bounded runtime. Curation proceeded from regenerated Orphanet structured evidence and fetched PubMed/DOI caches, without creating or hand-editing any references_cache/*.md files.

Evidence Scope Used

  • ORPHA:423461 for the exact disease record, MONDO and OMIM mappings, autosomal recessive inheritance, GNPTAB disease-gene association, epidemiology, and all structured HPO phenotype frequency rows.
  • PMID:20301730 for diagnostic enzyme testing, GNPTAB sequencing, management, surveillance, inheritance, and genetic counseling snippets, with the YAML noting that the cached GeneReviews chapter is archival/retired.
  • DOI:10.1136/jmg.2009.067736 and PMID:19197337 for GNPTAB causation, phosphotransferase deficiency, and residual-activity genotype-phenotype framing.
  • PMID:20367762 for natural history, lysosomal hydrolase disparity, skeletal radiographic changes, dysostosis multiplex, and osteodystrophy.
  • PMID:21466370 for autopsy and histopathology evidence covering lysosomal granular storage in multiple organs, cartilage, bone, and cardiac valve pathology.
  • PMID:29704188, PMID:10472261, PMID:12705498, and PMID:32818557 for adult skeletal disease, orthopedic intervention, physical therapy, pamidronate, and cardiac involvement.
  • PMID:30208878 for a GNPTAB-confirmed ML III alpha/beta case report and diagnostic use of enzyme and genetic testing.

Curation Conclusions

The curated model is biallelic GNPTAB pathogenic variation causing reduced UDP-N-acetylglucosamine-1-phosphotransferase activity. Loss of the mannose-6-phosphate recognition marker prevents efficient lysosomal targeting of hydrolases, leading to extracellular hydrolase leakage, intracellular lysosomal storage, and a multisystem but attenuated ML III phenotype. The most evidence-backed clinical axis is skeletal and joint degeneration, with secondary cardiac-valve, biochemical, ENT/hearing, growth, and mild cognitive manifestations. Current management in the cached literature is supportive and complication-directed, including physical therapy, orthopedic/carpal tunnel surgery, pamidronate for bone pain in limited human evidence, surveillance, and genetic counseling.